Search

Your search keyword '"Dimopoulos, M. A."' showing total 4 results
Start Over Author "Dimopoulos, M. A." Topic bone marrow Publication Year Range Last 10 years
4 results on '"Dimopoulos, M. A."'

1. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.

Author

Spanoudakis E, Papoutselis M, Terpos E, Dimopoulos MA, Tsatalas C, Margaritis D, Rahemtulla A, Kotsianidis I, and Karadimitris A

Subjects
Adult, Aged, Aged, 80 and over, Bone Marrow immunology, Bone Marrow pathology, Bone Marrow Cells metabolism, Bone Marrow Cells pathology, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Multiple Myeloma immunology, Multiple Myeloma metabolism, Multiple Myeloma pathology, Natural Killer T-Cells pathology, Up-Regulation genetics, Bone Marrow metabolism, Multiple Myeloma genetics, Natural Killer T-Cells metabolism, RANK Ligand genetics
Published
2016
Full Text
View/download PDF

2. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Author

Gkotzamanidou, M, Sfikakis, P P, Kyrtopoulos, S A, Souliotis, V L, Bamia, C, and Dimopoulos, M A

Subjects
MYELOMA proteins, DNA damage, BONE marrow, PLASMA cells, DNA repair, CANCER chemotherapy
Abstract

Background:Melphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown.Methods:Chromatin structure, transcriptional activity and DNA damage response signals were examined following ex vivo treatment with melphalan of both malignant bone marrow plasma cells (BMPCs) and peripheral blood mononuclear cells (PBMCs) of MM patients, responders (n=57) or non-responders (n=28) to melphalan therapy. PBMCs from healthy controls (n=25) were also included in the study.Results:In both BMPCs and PBMCs, the local chromatin looseness, transcriptional activity and repair efficiency of the transcribed strand (TS) were significantly higher in non-responders than in responders and lowest in healthy controls (all P<0.05). Moreover, we found that melphalan-induced apoptosis inversely correlated with the repair efficiency of the TS, with the duration of the inhibition of mRNA synthesis, phosphorylation of p53 at serine 15 and apoptosis rates being higher in responders than in non-responders (all P<0.001).Conclusions:Our findings provide a mechanistic basis for the link between DNA repair efficiency and response to melphalan therapy. Interestingly, the observation of these phenomena in PBMCs provides a novel approach for the prediction of response to anti-myeloma therapy. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

4. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Moreau, P, Miguel, JS, Sonneveld, Pieter, Mateos, MV, Zamagni, E, Avet-Loiseau, H, Hajek, R, Dimopoulos, MA, Ludwig, H, Einsele, H, Zweegman, S, Facon, T, Cavo, M, Terpos, E, Goldschmidt, H, Attal, M, Buske, C, Comm, EG, Moreau, P, San Miguel, J, Sonneveld, P, Mateos, M V, Zamagni, E, Avet-Loiseau, H, Hajek, R, Dimopoulos, M A, Ludwig, H, Einsele, H, Zweegman, S, Facon, T, Cavo, M, Terpos, E, Goldschmidt, H, Attal, M, Buske, C, Hematology, and CCA - Cancer Treatment and quality of life

Subjects
0301 basic medicine, Immunofixation, Pathology, medicine.medical_specialty, Skeletal survey, Medical Oncology, Asymptomatic, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Spinal cord compression, medicine, Humans, Stage (cooking), Multiple myeloma, Neoplasm Staging, biology, business.industry, Hematology, medicine.disease, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, biology.protein, Bone marrow, Radiology, medicine.symptom, business, Multiple Myeloma, Monoclonal gammopathy of undetermined significance, multiple myelma, ESMo, guidelines, Follow-Up Studies
Abstract

These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO) incidence and epidemiology Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all haematological malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at diagnosis of between 65 and 70 years; the mortality is 4.1/100 000/year. Almost all patients with MM evolve from an asymptomatic pre-malignant stage termed monoclonal gammopathy of undetermined significance (MGUS). MGUS progresses to MM at a rate of 1% per year. In some patients, an intermediate asymptomatic but more advanced pre-malignant stage termed smouldering (or indolent) multiple myeloma (SMM) can be recognised. SMM progresses to myeloma at a rate of 10% per year over the first 5 years following diagnosis, 3% per year over the following 5 years and 1.5% per year thereafter [1]. diagnosis Diagnosis of MM should be based on the following tests: [1] -Detection and evaluation of the monoclonal (M-) component by serum and/or urine protein electrophoresis (concentrate of 24 h urine collection); nephelometric quantification of IgG, IgA and IgM immunoglobulins; characterisation of the heavy and light chains by immunofixation; and serum-free light-chain (FLC) measurement; -Evaluation of bone marrow (BM) plasma cell infiltration: BM aspiration and/or biopsies are the standard options to evaluate the number and characteristics. Moreover, the BM sample should be used for cytogenetic/fluorescence in situ hybridization (FISH) studies and also has the potential for immunophenotypic and molecular investigations; -Evaluation of lytic bone lesions: a radiological skeletal bone survey, including spine, pelvis, skull, humeri and femurs is necessary. A magnetic resonance imaging (MRI) or computed tomography (CT) scan may be needed to evaluate symptomatic bony sites, even if the skeletal survey is negative and the patient has symptoms suggesting bone lesions. Moreover, MRI provides greater detail and is recommended whenever spinal cord compression is suspected. Fluorodeoxyglucose positron emission tomography is currently under evaluation but should not be systematically used; -Complete blood cell count, with differential serum creatinine and calcium level.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results